Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,457.00    41.00 (2.90%)
Bid:
1,456.00
Ask:
1,458.00
Spread: 2.00 (0.137%)
Market Cap: £3.10b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

10 Dec 2020 16:00

RNS Number : 2836I
Hikma Pharmaceuticals Plc
10 December 2020
 

Hikma Pharmaceuticals PLC

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Executive Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Pledge by Darhold Limited of 1,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of J.P. Morgan (Suisse) SA. Darhold Limited is defined as a Person Closely Associated with the Executive Chairman, who is a director of and shareholder in Darhold Limited

c)

Price(s) and volume(s)

Price(s): £0.00p

Volume(s): 1,500,000

d)

Aggregated information

Aggregated volume: 1,500,000

Price: £0.00p

e)

Date of the transaction

10 December 2020

f)

Place of the transaction

Amman

 

 

 Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Pledge by Darhold Limited of 1,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of J.P. Morgan (Suisse) SA. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman, who is a director of and shareholder in Darhold Limited.

c)

Price(s) and volume(s)

Price(s): £0.00p

Volume(s): 1,500,000

d)

Aggregated information

Aggregated volume: 1,500,000

Price: £0.00p

e)

Date of the transaction

10 December 2020

f)

Place of the transaction

Amman

Mohammed 'Ali' Al-Husry

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mohammed 'Ali' Al-Husry

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Pledge by Darhold Limited of 1,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of J.P. Morgan (Suisse) SA. Darhold Limited is defined as a Person Closely Associated with the the Non-Executive Director, who is a director of and shareholder in Darhold Limited.

c)

Price(s) and volume(s)

Price(s): £0.00p

Volume(s): 1,500,000

d)

Aggregated information

Aggregated volume: 1,500,000

Price: £0.00p

e)

Date of the transaction

10 December 2020

f)

Place of the transaction

Amman

 

Peter SpeirsCompany Secretary, responsible for releasing this announcement+44 (0) 20 7399 2760

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBUBDDCUBDGGG
Date   Source Headline
14th May 20154:27 pmRNSResult of AGM
14th May 20157:00 amRNSAGM Trading Update
12th May 20159:00 amRNSHikma launches caffeine citrate injection
15th Apr 20159:47 amRNSHolding(s) in Company
10th Apr 20153:19 pmRNSTotal Voting Rights
10th Apr 20157:00 amRNSDirector/PDMR Shareholding
9th Apr 201511:16 amRNSAnnual Information Update
9th Apr 201510:51 amRNSAnnual Financial Report
7th Apr 20153:03 pmRNSBlocklisting Interim Review
1st Apr 20155:13 pmRNSHikma prices debut $500 million five-year eurobond
31st Mar 20153:27 pmRNSStabilisation Notice
25th Mar 201512:23 pmRNSFixed income investor meetings
19th Mar 20151:45 pmRNSDirector/PDMR Shareholding
13th Mar 201511:34 amRNSHolding(s) in Company
11th Mar 20157:00 amRNSFinal Results
27th Jan 20152:13 pmRNSHikma Delivers Insights at World Economic Forum
23rd Jan 201511:44 amRNSDirector Declaration
21st Jan 201511:19 amRNSNotification of major interest in shares
15th Jan 201510:04 amRNSBlocklisting Interim Review
12th Jan 20157:00 amRNSHikma to launch colchicine 0.6mg capsules
7th Jan 201511:11 amRNSTotal Voting Rights
12th Nov 201412:14 pmRNSDirector/PDMR Shareholding
11th Nov 20141:22 pmRNSTotal Voting Rights
7th Nov 201411:12 amRNSNotification of major interest in shares
6th Nov 20147:00 amRNSDirectorate Change
6th Nov 20147:00 amRNSInterim Management Statement
24th Oct 20147:00 amRNSHikma announces receipt of Warning Letter from FDA
20th Oct 20145:18 pmRNSDirector/PDMR Shareholding
10th Oct 201411:44 amRNSStatement re Colchicine
10th Oct 20147:00 amRNSDirector/PDMR Shareholding
6th Oct 20143:58 pmRNSBlocklisting Interim Review
6th Oct 201411:23 amRNSTotal Voting Rights
30th Sep 20146:13 pmRNSRegulatory Approval Colchicine
17th Sep 20147:00 amRNSAcquisition
20th Aug 20144:00 pmRNSDividend Declaration
20th Aug 20147:00 amRNSInterim Results
7th Aug 20144:05 pmRNSNotice of Interim Results Announcement
28th Jul 20149:01 amRNSDirector/PDMR Shareholding
24th Jul 20149:08 amRNSAcquisition
15th Jul 20143:35 pmRNSAcquisition
14th Jul 20143:41 pmRNSTotal Voting Rights
27th Jun 20144:07 pmRNSDirector/PDMR Shareholding
23rd Jun 20142:20 pmRNSDirector/PDMR Shareholding
11th Jun 20143:11 pmRNSDirector/PDMR Shareholding
10th Jun 20145:13 pmRNSTotal Voting Rights
29th May 20149:45 amRNSDirector/PDMR Shareholding
29th May 20149:40 amRNSDirector/PDMR Shareholding
28th May 201412:00 pmRNSAcquisition
27th May 20149:53 amRNSDirector/PDMR Shareholding
15th May 20143:05 pmRNSResults of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.